From Wikipedia, the free encyclopedia
Medication for conditions affecting blood vessels
A vasoprotective is a medication which acts to alleviate or prevent conditions or diseases which affect the
blood vessels. The term is used in the
World Health Organization's
Anatomical Therapeutic Chemical Classification System to encompass therapeutic agents used in the treatment of
hemorrhoids or
varicose veins.
[1] The term may also be used to describe drugs which lower the risk of developing
hypercholesterolemia or
hypertension.
[2]
Examples of vasoprotectives include
1-methylnicotinamide,
[3]
estrogen,
[4]
tribenoside,
[5] and
valsartan.
[6]
More specifically, arterial vasoprotectors are called angioprotectors.
See also
References
-
^
"ATC/DDD Index". WHO Collaborating Centre for Drug Statistics Methodology. 2019-12-16. Retrieved 2020-01-28.
-
^ Henry PD, Cabello OA (1995). "Vasoprotection and antihypertensive therapy". Curr Opin Nephrol Hypertens. 4 (2): 197–200.
doi:
10.1097/00041552-199503000-00014.
PMID
7600051.
-
^ Domagala, T. B.; Szeffler, A.; Dobrucki, L. W.; Dropinski, J.; Polanski, S.; Leszczynska-Wiloch, M.; Kotula-Horowitz, K.; Wojciechowski, J.; Wojnowski, L.; Szczeklik, A.; Kalinowski, L. (2012).
"Nitric oxide production and endothelium-dependent vasorelaxation ameliorated by N1-methylnicotinamide in human blood vessels".
Hypertension. 59 (4): 825–832.
doi:
10.1161/HYPERTENSIONAHA.111.183210.
PMID
22353616.
S2CID
302943.
-
^ Wassmann K, Wassmann S, Nickenig G (November 2005).
"Progesterone antagonizes the vasoprotective effect of estrogen on antioxidant enzyme expression and function". Circ. Res. 97 (10): 1046–54.
doi:
10.1161/01.RES.0000188212.57180.55.
PMID
16195479.
-
^ Lorenc Z, Gökçe Ö (2016).
"Tribenoside and lidocaine in the local treatment of hemorrhoids: an overview of clinical evidence". Eur Rev Med Pharmacol Sci. 20 (12): 2742–51.
PMID
27383331.
-
^ Okumura M, Iwai M, Ide A, Mogi M, Ito M, Horiuchi M (September 2005).
"Sex difference in vascular injury and the vasoprotective effect of valsartan are related to differential AT2 receptor expression". Hypertension. 46 (3): 577–83.
doi:
10.1161/01.HYP.0000178564.14464.80.
PMID
16103268.